Table 3. Available studies in ABC with PARPi.
| Study | n | PARPi | Subgroups | Line | ORR (%) | PFS (Median in months, 95%IC) |
OS (Median in months, 95% IC) |
|---|---|---|---|---|---|---|---|
| LUCY [8] | 252 | Olaparib | g/sBRCA1/2m | 54% 1 L | 48.6 | 8.1 (6.9–8.6) | NA |
| Dawood [9] | 586 | Olaparib talazoparib others |
g/sBRCA1/2m | 31% 1 L 51% 2 L 30% ≥3 L |
NA | NA | 23.0 (NA) |
| Batalini et al [10] | 62 | NA | No gBRCAm gBRCAm |
NA | NA | 7.7 (NA) 5.5 (NA) |
15.0 (NA) 11.5 (NA) |
| TBCRC-048 [11] | 20 | Olaparib | g/sBRCA1/2m g/sHRRm |
≥3 L | 33.0 | 13.3 (12–NA) | NA |
| TBB [12] | 13 | Talazoparib | g/sHRRm | NA | 31.0 | NA | NA |
| OlympiAD [13] | 302 | Olaparib | gBRCA1/2m | 29% 1 L | 59.9 | 7.4 (NA) | 19.3 (NA) |
| EMBRACA [14] | 431 | Talazoparib | gBRCA1/2m | 39% 1 L 37% 2 L 24% ≥3 L |
62.6 | 8.6 (7.2–9.3) | 19.3 (16.6–22.5) |
| LuciA-15 | 51 | Olaparib talazoparib |
g/sBRCA1/2m g/sHRRm |
23.5% 1 L 31.4% 2 L 45.1% ≥3 L |
47.0 | 7.7 (5.6–14.7) | 26.67 (13.5–NR) |
PARPi, PARP inhibitor; g/sBRCA1/2, germline/somatic BRCA 1 or 2 mutations; g/sHRR, germline/somatic Homologous Recombination Repair genes mutation; ORR, objective response rate; PFS, pprogression-free survival; NA, not available or not specified; NR, not reached